Literature DB >> 8124674

Monosialoganglioside GM1 blood levels in maternal and newborn umbilical cord blood at birth.

V Zanardo1, L Marchesini, G Kirschner.   

Abstract

Blood levels of the monosialoganglioside GM1 (nomenclature according to Svennerholm) were tested at birth in the umbilical cord of 37 neonates and their mothers. Comparisons were made based on gestational age and modality of delivery. GM1 blood levels at birth were significantly higher in mothers than in newborns (373.66 +/- 56.83 ng/ml vs 217.95 +/- 21.24 ng/ml; P < 0.01). Newborns delivered by cesarean section showed levels of GM1 significantly higher than those delivered vaginally (298.97 +/- 38.55 ng/ml vs 169.62 +/- 12.62 ng/ml; P < 0.01), and preterm newborns had significantly higher levels of GM1 than full-term newborns (253.50 +/- 40.83 ng/ml vs 193.71 +/- 21.74 ng/ml; P < 0.01). No differences in blood levels of GM1 were observed in the mothers in relation to length of pregnancy or modality of delivery. The higher levels of GM1 observed in preterm newborns indicate an increased turnover and/or enhanced bioavailability of the monosialoganglioside GM1 for the developing central nervous system. Further data are required to evaluate the significance of the increased cord levels of GM1 in neonates after cesarean section.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8124674     DOI: 10.1007/bf00393551

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  21 in total

Review 1.  Glutamate and the pathophysiology of hypoxic--ischemic brain damage.

Authors:  S M Rothman; J W Olney
Journal:  Ann Neurol       Date:  1986-02       Impact factor: 10.422

2.  GM1 ganglioside stimulates the regeneration of dopaminergic neurons in the central nervous system.

Authors:  G Toffano; G Savoini; F Moroni; G Lombardi; L Calza; L F Agnati
Journal:  Brain Res       Date:  1983-02-14       Impact factor: 3.252

3.  Thresholds in cerebral ischemia - the ischemic penumbra.

Authors:  J Astrup; B K Siesjö; L Symon
Journal:  Stroke       Date:  1981 Nov-Dec       Impact factor: 7.914

4.  GM1 ganglioside therapy in acute ischemic stroke. Italian Acute Stroke Study--Hemodilution + Drug.

Authors:  C Argentino; M L Sacchetti; D Toni; G Savoini; E D'Arcangelo; F Erminio; F Federico; F F Milone; V Gallai; D Gambi
Journal:  Stroke       Date:  1989-09       Impact factor: 7.914

5.  Promotion of neuritogenesis in mouse neuroblastoma cells by exogenous gangliosides. Relationship between the effect and the cell association of ganglioside GM1.

Authors:  L Facci; A Leon; G Toffano; S Sonnino; R Ghidoni; G Tettamanti
Journal:  J Neurochem       Date:  1984-02       Impact factor: 5.372

6.  Interaction of GM1 ganglioside with PC12 pheochromocytoma cells: serum- and NGF-dependent effects on neuritic growth (and proliferation).

Authors:  R Katoh-Semba; S D Skaper; S Varon
Journal:  J Neurosci Res       Date:  1984       Impact factor: 4.164

7.  Competitive binding assay for quantitative determination of GM1 ganglioside in plasma and cerebrospinal fluid.

Authors:  G Kirschner; M Bassan; M P Facco; G Ferrari; L Callegaro
Journal:  J Pharm Biomed Anal       Date:  1992 Feb-Mar       Impact factor: 3.935

Review 8.  Gangliosides and synaptic transmission.

Authors:  H Rahmann; W Probst; M Mühleisen
Journal:  Jpn J Exp Med       Date:  1982-12

9.  Ganglioside GM1 overcomes serum inhibition of neuritic outgrowth.

Authors:  S D Skaper; S Varon
Journal:  Int J Dev Neurosci       Date:  1985       Impact factor: 2.457

10.  GM1 ganglioside accelerates neurite outgrowth from primary peripheral and central neurons under selected culture conditions.

Authors:  S D Skaper; R Katoh-Semba; S Varon
Journal:  Brain Res       Date:  1985-11       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.